Parsabiv FDA Approval History
FDA Approved: Yes (First approved February 7, 2017)
Brand name: Parsabiv
Generic name: etelcalcetide
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Secondary Hyperparathyroidism
Parsabiv (etelcalcetide) is a calcium-sensing receptor agonist indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Development timeline for Parsabiv
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.